Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Study of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer

3. september 2026 opdateret af: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

A Randomized, Open-Label, Multicenter Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of HB1801 Versus Docetaxel (Taxotere®) in Patients With Advanced Breast Cancer

This is a randomized, open-label, multicenter Phase Ⅲ clinical trial designed to evaluate the efficacy and safety of HB1801 versus Taxotere® in patients with HER2-negative advanced breast cancer.

Studieoversigt

Status

Ikke rekrutterer endnu

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

430

Fase

  • Fase 3

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Clinical Trials Information Group Officer
  • Telefonnummer: 86-0311-69085587
  • E-mail: ctr-contact@cspc.cn

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

  • Voksen
  • Ældre voksen

Tager imod sunde frivillige

Ingen

Beskrivelse

Inclusion Criteria:

  • 1. Age: 18-75 years (Whichever is on the day of signing the informed consent form).
  • 2. Subjects have histologically or cytologically confirmed breast cancer at unresectable,recurrent/metastatic stage, with the requirements below based on the most recent pathological report:

    1. HER2-negative confirmed by histological or cytological testing;
    2. Pathological report is available to confirm HR status.
  • 3. Assessed by the Investigator as suitable for single-agent docetaxel therapy.
  • 4. At least one extracranial measurable lesion at baseline according to RECIST 1.1 criteria.
  • 5. Has adequate organ and system functions within 7 days prior to the first dose.
  • 6. Eastern Cooperative Oncology Group performance status of 0 or 1.
  • 7. Expected survival ≥ 3 months.

Exclusion Criteria:

  • 1. Has received prior taxane-containing single-agent or combination regimens, and have disease progression during salvage therapy for unresectable locally advanced or metastatic breast cancer (has received at least 2 cycles), or developed recurrent-metastatic disease within 12 months following adjuvant therapy.
  • 2. History of severe allergy or hypersensitivity reactions (Grade ≥3 per NCI-CTCAE Version 6.0) to human serum albumin or docetaxel and/or contraindications thereto, or history of severe allergy and/or contraindications to glucocorticoids.
  • 3. Untreated active brain metastases (including brain or leptomeningeal metastases). Subjects with treated brain metastases may be enrolled if lesions are stable without evidence of new or enlarging pre-existing brain metastases.
  • 4. With a history of other primary malignant tumors within 5 years before administration.
  • 5. Presence of serous cavity effusion requiring drainage or diuretic therapy within 2 weeks prior to the first dose.
  • 6. Severe neurological diseases (e.g., epilepsy, dementia, etc.) and Grade ≥2 peripheral neuropathy.
  • 7. Receipt of systemic glucocorticoid therapy within 14 days prior to the first dose.
  • 8. Current clinically significant abnormal interstitial lung disease.
  • 9. History of severe cardiovascular and cerebrovascular diseases within 6 months prior to the first dose.
  • 10. Has arterial or venous thromboembolism (e.g., lower-extremity deep vein thrombosis, lower-extremity arterial embolism, pulmonary embolism, etc.) within 6 months prior to the first dose. Stable thrombus is permitted for enrollment if the Investigator assesses no associated cardiovascular risk.
  • 11. Severe chronic or active infection requiring intravenous antibacterial, antifungal, or antiviral therapy within 2 weeks prior to the first dose.
  • 12. Has undergone major visceral organ surgery (excluding puncture biopsy or infusion device implantation) within 4 weeks prior to the first dose, or who require major visceral organ surgery during the study period.
  • 13. Receipt of chemotherapy, targeted therapy, immunotherapy, endocrine therapy, or other investigational study drug within 4 weeks or 5 half-lives prior to the first dose (whichever is shorter, with a minimum of 2 weeks); receipt of radiotherapy within 2 weeks prior to the first dose; receipt of traditional Chinese medicine with anti-tumor indications within 2 weeks prior to the first dose.
  • 14. Toxicities from all prior anti-tumor therapies have not recovered to Grade 1 or less prior to the first dose.
  • 15. Has received powerful CYP3A4 inhibitor or inducer within 2 weeks before the first dose.
  • 16. Has active hepatitis B infection, hepatitis C infection, positive HIV antibody, or active syphilis.
  • 17. Concurrent participation in another interventional clinical study.
  • 18. Any other conditions that, in the Investigator's opinion, render the participant unsuitable for participation in this clinical trial.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: HB1801
HB1801, 100 mg/m² in Cycle 1, 75 mg/m² starting from Cycle 2, once every 3 weeks (Q3W), intravenous infusion over 60 minutes.
Eksperimentel: Docetaxel (Taxotere®)
Docetaxel (Taxotere®), 75 mg/m², Q3W, intravenous infusion over 60 minutes.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Progression-free Survival (PFS)
Tidsramme: up to approximately 2 years after the first enrollment
PFS was defined as the time from the date of randomization to the date of progressive disease (as per RECIST v1.1) or death due to any cause.
up to approximately 2 years after the first enrollment

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Objective Response Rate (ORR) assessed per RECIST v1.1
Tidsramme: up to approximately 2 years after the first enrollment
ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) assessed by investigator was defined as the percentage of participants with complete response (CR) or partial response (PR).
up to approximately 2 years after the first enrollment
Duration of Response (DOR)
Tidsramme: up to approximately 2 years after the first enrollment
DOR by investigator assessment according to RECIST 1.1 in participants with CR or PR, defined as the time from the first documented CR/PR to PD or death.
up to approximately 2 years after the first enrollment
Disease Control Rate (DCR)
Tidsramme: up to approximately 2 years after the first enrollment
DCR by investigator assessment according to RECIST 1.1, defined as the percentage of participants with CR, PR, or stable disease (SD) lasting at least 6 weeks.
up to approximately 2 years after the first enrollment
Overall Survival (OS)
Tidsramme: up to approximately 2 years after the first enrollment
OS was defined as the time from the date of randomization until death due to any cause regardless of whether the participant withdrew from study therapy or received another subsequent anticancer therapy.
up to approximately 2 years after the first enrollment
The incidence and severity of adverse events (AE) and severe adverse events (SAE)
Tidsramme: up to approximately 2 years after the first enrollment
up to approximately 2 years after the first enrollment
Plasma concentration of docetaxel (free and total)
Tidsramme: After completion of infusion administration on Day 1 of Cycle 1
After completion of infusion administration on Day 1 of Cycle 1

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

31. august 2026

Primær færdiggørelse (Anslået)

1. juni 2028

Studieafslutning (Anslået)

1. juni 2029

Datoer for studieregistrering

Først indsendt

28. august 2026

Først indsendt, der opfyldte QC-kriterier

3. september 2026

Først opslået (Faktiske)

4. september 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

4. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

3. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner